Abstract Background In the EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial) treatment with sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin significantly reduced heart failure hospitalization (HHF) in patients type 2 diabetes mellitus (T2D) and established cardiovascular disease. The early separation of HHF event curves within first 3 months suggest that i...

INTRODUCTION The first cardiovascular safety trial in the sodium-glucose co-transporter-2 (SGLT2) inhibitor drug class, the Empagliflozin Cardiovascular Outcomes and Mortality in Type 2 Diabetes (EMPA-REG OUTCOME) trial, demonstrated significant cardiovascular risk reduction with empagliflozin. It is currently not clear what proportions of people with type 2 diabetes (T2DM) have the same high c...

INTRODUCTION When first line therapy with metformin is insufficient for patients with type 2 diabetes (T2D), the optimal adjunctive therapy is unclear. We assessed the efficacy and safety of adjunctive antidiabetic agents in patients with inadequately controlled T2D on metformin alone. MATERIALS AND METHODS A search of MEDLINE and CENTRAL, clinicaltrials.gov, regulatory websites was performed...

The Renal sodium-dependent glucose co-transporter 2 (SGLT2) is one of the most promising targets for the treatment of type 2 diabetes. Two SGLT2 inhibitors, dapagliflozin, and canagliflozin, have already been approved for use in USA and Europe; several additional compounds are also being developed for this purpose. Based on the in vitro IC50 values and plasma concentration of dapagliflozin meas...

Abstract Background In the EMPEROR-Preserved trial, empagliflozin reduced risk of hospitalizations for heart failure (HHF) or cardiovascular (CV) death in patients with and preserved ejection fraction (HFpEF). Almost one five trial were not on baseline diuretic therapy. Purpose To evaluate efficacy safety according to treatment, as well change therapy after initiation empagliflozin. Methods Pat...